Open AccessSudden visual loss as an initial manifestation of chronic myeloid leukemia
Author(s) -
Ahmed N Buzaid,
Ali Alamri
Publication year - 2017
Publication title -
saudi journal of medicine and medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 2
eISSN - 1658-631X
pISSN - 2321-4856
DOI - 10.4103/sjmms.sjmms_35_16
Subject(s) - medicine , chronic myelogenous leukemia , philadelphia chromosome , nilotinib , dasatinib , granulocytosis , thrombocytosis , asymptomatic , myeloid leukemia , abl , dermatology , pathology , imatinib , chromosomal translocation , leukemia , immunology , tyrosine kinase , genetics , gene , platelet , granulocyte , receptor , biology
Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by anemia, granulocytosis and granulocytic immaturity, basophilia, thrombocytosis and splenomegaly. It is associated with a reciprocal chromosomal translocation t (q34; q11), resulting in a breakpoint cluster region-Abelson fusion gene (Philadelphia chromosome). Ophthalmic manifestations as the first and the only presentation of CML in patients are very rare. Ocular lesions in CML patients are frequently asymptomatic, and thus all patients should undergo an eye evaluation at the initial diagnosis. Here, we report a previously healthy 36-year-old Saudi male who initially presented with progressive loss of vision. On examination, he was found to have a bilateral retinal hemorrhage. The investigations revealed findings consistent with CML. The patient was treated with tyrosine kinase inhibitors, and he had complete remission, including full recovery of his vision.